GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin

Bayer539 enrolled

Overview

To evaluate the effectiveness of Glucobay when combined with a basal insulin under daily-life treatment conditions in a large sample of Korean patients.

Study Type

OBSERVATIONAL

Enrollment

539

Conditions

Diabetes Mellitus

Interventions

Acarbose (Glucobay, BAYG5421)DRUG

Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed written informed consent * Age ≥ 18 years * Diagnosed of type 2 diabetes for at least 6 months prior to enrollment * Patients treated with stable dose of a basal insulin (insulin glargine or insulin detemir) at least 2 months * HbA1C≥7.5 and ≤10.0% Exclusion Criteria: * Exclusion criteria must be read in conjunction with the local product information

Locations (1)

Unnamed facility

Many Locations, South Korea

Outcomes

Primary Outcomes

Change in HbA1c

Time frame: After 20 weeks

Secondary Outcomes

Duration and dose of acarbose treatment

Time frame: After 20 weeks

Postprandial Blood Glucose

Time frame: After 20 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.